Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.

Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bossé D, Wankowicz SM, Cullen D, Horak C, Wind-Rotolo M, Tracy A, Giannakis M, Hodi FS, Drake CG, Ball MW, Allaf ME, Snyder A, Hellmann MD, Ho T, Motzer RJ, Signoretti S, Kaelin WG Jr, Choueiri TK, Van Allen EM.

Science. 2018 Feb 16;359(6377):801-806. doi: 10.1126/science.aan5951. Epub 2018 Jan 4.

2.

Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.

Messai Y, Gad S, Noman MZ, Le Teuff G, Couve S, Janji B, Kammerer SF, Rioux-Leclerc N, Hasmim M, Ferlicot S, Baud V, Mejean A, Mole DR, Richard S, Eggermont AM, Albiges L, Mami-Chouaib F, Escudier B, Chouaib S.

Eur Urol. 2016 Oct;70(4):623-632. doi: 10.1016/j.eururo.2015.11.029. Epub 2015 Dec 23.

PMID:
26707870
3.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

4.

[Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].

Peters I, Tezval H, Kramer MW, Wolters M, Grünwald V, Kuczyk MA, Serth J.

Aktuelle Urol. 2015 Nov;46(6):481-5. doi: 10.1055/s-0041-106169. Epub 2015 Nov 11. German.

PMID:
26560846
5.

Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.

Kawakami F, Sircar K, Rodriguez-Canales J, Fellman BM, Urbauer DL, Tamboli P, Tannir NM, Jonasch E, Wistuba II, Wood CG, Karam JA.

Cancer. 2017 Dec 15;123(24):4823-4831. doi: 10.1002/cncr.30937. Epub 2017 Aug 22.

6.

[Advances in immune checkpoint inhibitors in gastrointestinal cancer].

Zhu XR, Zheng LZ.

Zhonghua Zhong Liu Za Zhi. 2017 Sep 23;39(9):646-649. doi: 10.3760/cma.j.issn.0253-3766.2017.09.002. Review. Chinese.

PMID:
28926891
7.

Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.

Suarez ER, Chang de K, Sun J, Sui J, Freeman GJ, Signoretti S, Zhu Q, Marasco WA.

Oncotarget. 2016 Jun 7;7(23):34341-55. doi: 10.18632/oncotarget.9114.

8.

Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.

Mikami S, Mizuno R, Kondo T, Shinohara N, Nonomura N, Ozono S, Eto M, Tatsugami K, Takayama T, Matsuyama H, Kishida T, Oya M; Japanese Society of Renal Cancer.

Cancer Sci. 2019 Jun;110(6):1820-1828. doi: 10.1111/cas.14019. Epub 2019 May 13.

9.

Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?

Nebot-Bral L, Coutzac C, Kannouche PL, Chaput N.

Bull Cancer. 2019 Feb;106(2):105-113. doi: 10.1016/j.bulcan.2018.08.007. Epub 2018 Oct 17. Review.

PMID:
30342749
10.

A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.

Nunes-Xavier CE, Angulo JC, Pulido R, López JI.

Curr Urol Rep. 2019 Jan 15;20(1):1. doi: 10.1007/s11934-019-0866-8. Review.

PMID:
30645700
11.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.

12.

BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.

Piva F, Santoni M, Matrana MR, Satti S, Giulietti M, Occhipinti G, Massari F, Cheng L, Lopez-Beltran A, Scarpelli M, Principato G, Cascinu S, Montironi R.

Expert Rev Mol Diagn. 2015;15(9):1201-10. doi: 10.1586/14737159.2015.1068122. Epub 2015 Jul 11. Review.

PMID:
26166446
13.

Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?

Sabanathan D, Park JJ, Marquez M, Francisco L, Byrne N, Gurney H.

Oncologist. 2017 Dec;22(12):1470-1477. doi: 10.1634/theoncologist.2017-0159. Epub 2017 Nov 16.

14.

Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.

Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, Spektor A, Krishnan M, Ott PA, Balboni TA, Hodi FS, Schoenfeld JD.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):344-351. doi: 10.1016/j.ijrobp.2017.02.003. Epub 2017 Feb 11.

PMID:
28463153
15.

[Immunotherapy of Renal Cell Carcinoma].

Poprach A, Lakomý R, Büchler T.

Klin Onkol. Winter 2017;30(Supplementum3):55-61. doi: 10.14735/amko20173S55. Review. Czech.

PMID:
29239194
16.

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD.

J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200/JCO.2017.75.3384. Epub 2018 Jan 16. Erratum in: J Clin Oncol. 2018 Jun 1;36(16):1645.

17.

Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.

Atkins MB, Clark JI, Quinn DI.

Ann Oncol. 2017 Jul 1;28(7):1484-1494. doi: 10.1093/annonc/mdx151. Review.

PMID:
28383639
18.

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.

Hargadon KM, Johnson CE, Williams CJ.

Int Immunopharmacol. 2018 Sep;62:29-39. doi: 10.1016/j.intimp.2018.06.001. Epub 2018 Jul 2. Review.

PMID:
29990692
19.

Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.

Ghatalia P, Zibelman M, Geynisman DM, Plimack ER.

Curr Treat Options Oncol. 2017 Jan;18(1):7. doi: 10.1007/s11864-017-0458-0. Review.

PMID:
28210995
20.

Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.

Zhang X, Shi X, Li J, Hu Z, Gao J, Wu S, Long Z.

Cancer Sci. 2019 Jan;110(1):31-39. doi: 10.1111/cas.13842. Epub 2018 Dec 1.

Supplemental Content

Support Center